Last reviewed · How we verify
low-intensity statin plus ezetimibe
A combination therapy that reduces LDL cholesterol through dual inhibition of cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe).
A combination therapy that reduces LDL cholesterol through dual inhibition of cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe). Used for Hypercholesterolemia and dyslipidemia management, Cardiovascular risk reduction in patients requiring LDL cholesterol lowering.
At a glance
| Generic name | low-intensity statin plus ezetimibe |
|---|---|
| Sponsor | Seung-Whan Lee, M.D., Ph.D. |
| Drug class | Combination lipid-lowering agent (statin + ezetimibe) |
| Target | HMG-CoA reductase (statin component); NPC1L1 transporter (ezetimibe component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low-intensity statins inhibit HMG-CoA reductase to decrease hepatic cholesterol production, while ezetimibe blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter to reduce dietary and biliary cholesterol absorption in the intestine. Together, they provide complementary mechanisms to lower circulating LDL cholesterol levels more effectively than either agent alone at lower individual doses.
Approved indications
- Hypercholesterolemia and dyslipidemia management
- Cardiovascular risk reduction in patients requiring LDL cholesterol lowering
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Gastrointestinal upset
- Headache
Key clinical trials
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
- Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM) (PHASE4)
- Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry
- Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (NA)
- Low Dose Statins, Ezetimibe and Nutraceuticals (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low-intensity statin plus ezetimibe CI brief — competitive landscape report
- low-intensity statin plus ezetimibe updates RSS · CI watch RSS
- Seung-Whan Lee, M.D., Ph.D. portfolio CI